NCT04089891: A trial that was reported late by Masonic Cancer Center, University of Minnesota
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT04089891 |
|---|---|
| Title | A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 31, 2019 |
| Completion date | Oct. 31, 2024 |
| Required reporting date | Oct. 31, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 3, 2020 |
| Days late | None |